Key facts
- This page summarizes Robert E. Landry's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Feb 2024, 16:08.
Robert E. Landry - 02 Feb 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)
- Reporting relationship
- EVP Finance CFO
- Issuer ticker
- REGN
- Reported as of
- 02 Feb 2024
- Net transaction value
- -$117,227
- SEC form
- 4
- Accepted by SEC
- 06 Feb 2024, 16:08:17 UTC
- Prior SEC filing
- 02 Feb 2024
- Next SEC filing
- 11 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/**Robert E. Landry
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Landry filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 06 Feb 2024.
Change
- Previous filing in this sequence was filed on 02 Feb 2024.
- Current net transaction value: -$117,227.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
REGN
transaction
Common Stock
Options Exercise
- Transaction value
- $151,592
- Shares
- +400
- Change %
- +1.7%
- Price
- $378.98
- Shares after
- 23,974
- Date
- 02 Feb 2024
- Ownership
- Direct
REGN
transaction
Common Stock
Tax liability
- Transaction value
- $268,819
- Shares
- -281
- Change %
- -1.2%
- Price
- $956.65
- Shares after
- 23,693
- Date
- 02 Feb 2024
- Ownership
- Direct
REGN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 270
- Date
- 02 Feb 2024
- Ownership
- By 401(k) Plan
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
REGN
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -400
- Change %
- -3.3%
- Price
- $0.000000
- Shares after
- 11,787
- Date
- 02 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 400
- Exercise price
- $378.98
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option award vests in four equal annual installments, commencing one year after the date of grant.